We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Molecular Devices

Molecular Devices provides innovative bioanalytical solutions for protein and cell biology in life science research, ... read more Featured Products: More products

Download Mobile App




Seropositivity Thresholds Defined for Use in Trachoma Elimination Studies

By LabMedica International staff writers
Posted on 01 Feb 2017
Trachoma is caused by ocular infection with the bacterium Chlamydia trachomatis and it is the leading infectious cause of blindness worldwide. More...
It is estimated that over 200 million people in 42 countries are at risk from trachoma blindness.

Individuals who have previously been infected with C. trachomatis carry specific antibodies in their blood. Recent studies have suggested that these antibodies may be a good way to estimate the intensity of transmission of this bacterium in a population. Among people who do have antibodies (seropositives) there is variation in the amount that is detectable in their blood.

A team of scientists led by those at the London School of Hygiene and Tropical Medicine examined and diagnosed trachoma in different populations and collected dried blood spots 952 children aged 1 to 9 years in Laos and 2,700 in Uganda and from 1,868 people aged 1 to 90 years in The Gambia, in 2014. Dried blood spots (DBS) were tested for antibodies against the secreted C. trachomatis protein Pgp3 using enzyme-linked immunosorbent assays (ELISA). Optical density of the ELISAs was read at 450 nm (OD450) on a Spectramax M3 plate reader.

The authors of the study estimated seroprevalence at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximization algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimize Youden’s J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples.

The authors concluded that internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. They propose that future serological analyses in trachoma use a finite mixture model or expectation-maximization algorithm as a means of setting the threshold for ELISA data. This will facilitate standardization and harmonization between studies and eliminate the need to establish and maintain a global calibration standard. The study was published on January 18, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.